Literature DB >> 31720993

The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease.

Naoki Nishiyama1, Takayuki Honda1, Manabu Sema1, Tatsuo Kawahara1, Yasuto Jin2, Ichiro Natsume3, Tomoshige Chiaki4, Takaaki Yamashita5, Yoshikazu Tsukada6, Reiko Taki7, Yoshihiro Miyashita8, Kazuhito Saito9, Tomoya Tateishi1, Hiroyuki Sakashita1,3,10, Yasunari Miyazaki11.   

Abstract

BACKGROUND: Acute exacerbation (AE) of interstitial lung disease (ILD) is a fatal adverse event in the treatment of lung cancer patients with ILD. The value of pre-treatment radiological findings obtained by high-resolution computed tomography for the detection of anticancer treatment-related AE of ILD has not been established.
METHODS: Two medical record-based retrospective studies were performed. The chemotherapy cohort included 105 lung cancer patients with ILD who received chemotherapy at Tokyo Medical and Dental University between October 2008 and December 2017. The immune checkpoint inhibitor (ICI) cohort included 48 advanced non-small cell lung cancer patients with ILD treated with ICIs at nine institutions between January 2016 and September 2018. Variables were compared between AE-positive and -negative groups. Candidate variables were analyzed by multivariate logistic regression. A P value < 0.05 was considered statistically significant.
RESULTS: Anticancer treatment-related AE of ILD occurred in 12 patients (11.4%) in the chemotherapy cohort and seven patients (14.5%) in the ICI cohort. In the multivariate logistic regression analysis, ground-glass attenuation (GGA) score was the only factor significantly associated with the development of AE of ILD in both cohorts (P = 0.037 and 0.01 in the chemotherapy and ICI cohorts, respectively).
CONCLUSION: Evaluation of GGA may help predict anticancer treatment-related AE of ILD.

Entities:  

Keywords:  Acute exacerbation; Chemotherapy; HRCT score; Immune checkpoint inhibitor; Interstitial pneumonia

Mesh:

Substances:

Year:  2019        PMID: 31720993     DOI: 10.1007/s10147-019-01576-x

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  41 in total

1.  Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Kristel Vandormael; Antonio Riccio; Jing Yang; M Catherine Pietanza; Julie R Brahmer
Journal:  J Clin Oncol       Date:  2019-01-08       Impact factor: 44.544

2.  Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease.

Authors:  Hirotsugu Kenmotsu; Tateaki Naito; Keita Mori; Ryo Ko; Akira Ono; Kazushige Wakuda; Hisao Imai; Tetsuhiko Taira; Haruyasu Murakami; Masahiro Endo; Toshiaki Takahashi
Journal:  Cancer Chemother Pharmacol       Date:  2015-01-07       Impact factor: 3.333

3.  A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease.

Authors:  Masaki Hanibuchi; Soji Kakiuchi; Shinji Atagi; Fumitaka Ogushi; Eiji Shimizu; Takashi Haku; Yuko Toyoda; Masahiko Azuma; Mayo Kondo; Hiroshi Kawano; Kenji Otsuka; Satoshi Sakaguchi; Hiroshi Nokihara; Hisatsugu Goto; Yasuhiko Nishioka
Journal:  Lung Cancer       Date:  2018-09-12       Impact factor: 5.705

4.  The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer.

Authors:  Hirotsugu Kenmotsu; Tateaki Naito; Madoka Kimura; Akira Ono; Takehito Shukuya; Yukiko Nakamura; Asuka Tsuya; Kyoichi Kaira; Haruyasu Murakami; Toshiaki Takahashi; Masahiro Endo; Nobuyuki Yamamoto
Journal:  J Thorac Oncol       Date:  2011-07       Impact factor: 15.609

5.  Pulmonary Resection for Lung Cancer in Patients With Idiopathic Interstitial Pneumonia.

Authors:  Takahiro Omori; Michihiko Tajiri; Tomohisa Baba; Takashi Ogura; Tae Iwasawa; Koji Okudela; Tamiko Takemura; Mari S Oba; Takamitsu Maehara; Haruhiko Nakayama; Masahiro Tsuboi; Munetaka Masuda
Journal:  Ann Thorac Surg       Date:  2015-06-23       Impact factor: 4.330

6.  Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer.

Authors:  Yasunori Enomoto; Naoki Inui; Terufumi Kato; Tomohisa Baba; Masato Karayama; Yutaro Nakamura; Takashi Ogura; Takafumi Suda
Journal:  Lung Cancer       Date:  2016-03-30       Impact factor: 5.705

7.  Computed tomography in pulmonary emphysema.

Authors:  P R Goddard; E M Nicholson; G Laszlo; I Watt
Journal:  Clin Radiol       Date:  1982-07       Impact factor: 2.350

8.  Interstitial Lung Disease in India. Results of a Prospective Registry.

Authors:  Sheetu Singh; Bridget F Collins; Bharat B Sharma; Jyotsna M Joshi; Deepak Talwar; Sandeep Katiyar; Nishtha Singh; Lawrence Ho; Jai Kumar Samaria; Parthasarathi Bhattacharya; Rakesh Gupta; Sudhir Chaudhari; Tejraj Singh; Vijay Moond; Sudhakar Pipavath; Jitesh Ahuja; Ravindran Chetambath; Aloke G Ghoshal; Nirmal K Jain; H J Gayathri Devi; Surya Kant; Parvaiz Koul; Raja Dhar; Rajesh Swarnakar; Surendra K Sharma; Dhrubajyoti J Roy; Kripesh R Sarmah; Bhavin Jankharia; Rodney Schmidt; Santosh K Katiyar; Arpita Jindal; Daya K Mangal; Virendra Singh; Ganesh Raghu
Journal:  Am J Respir Crit Care Med       Date:  2017-03-15       Impact factor: 21.405

9.  Immune Inflammation and Disease Progression in Idiopathic Pulmonary Fibrosis.

Authors:  Elisabetta Balestro; Fiorella Calabrese; Graziella Turato; Francesca Lunardi; Erica Bazzan; Giuseppe Marulli; Davide Biondini; Emanuela Rossi; Alessandro Sanduzzi; Federico Rea; Chiara Rigobello; Dario Gregori; Simonetta Baraldo; Paolo Spagnolo; Manuel G Cosio; Marina Saetta
Journal:  PLoS One       Date:  2016-05-09       Impact factor: 3.240

Review 10.  Acute Exacerbation in Interstitial Lung Disease.

Authors:  Gabriela Leuschner; Jürgen Behr
Journal:  Front Med (Lausanne)       Date:  2017-10-23
View more
  6 in total

1.  Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors.

Authors:  Yasuki Uchida; Daisuke Kinose; Yukihiro Nagatani; Sachiko Tanaka-Mizuno; Hiroaki Nakagawa; Kentaro Fukunaga; Masafumi Yamaguchi; Yasutaka Nakano
Journal:  BMC Cancer       Date:  2022-05-16       Impact factor: 4.638

2.  Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.

Authors:  Stephen W Reese; Eugene Cone; Maya Marchese; Brenda Garcia; Wesley Chou; Asha Ayub; Kerry Kilbridge; Gerald Weinhouse; Quoc-Dien Trinh
Journal:  Lung       Date:  2021-02-22       Impact factor: 2.584

3.  Outcomes of Patients With Interstitial Lung Disease Receiving Programmed Cell Death 1 Inhibitors: A Retrospective Case Series.

Authors:  Ioana A Dobre; Angela J Frank; Kristin M D'Silva; David C Christiani; Daniel Okin; Amita Sharma; Sydney B Montesi
Journal:  Clin Lung Cancer       Date:  2021-02-04       Impact factor: 4.785

4.  Risk factors for acute exacerbation in lung cancer complicated by interstitial lung disease with slight reticular shadows.

Authors:  Yutaka Takahara; Takuya Tanaka; Yoko Ishige; Ikuyo Shionoya; Kouichi Yamamura; Takashi Sakuma; Kazuaki Nishiki; Keisuke Nakase; Masafumi Nojiri; Ryo Kato; Shohei Shinomiya; Yuki Fujimoto; Taku Oikawa; Shiro Mizuno
Journal:  Thorac Cancer       Date:  2021-08-18       Impact factor: 3.500

5.  Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies.

Authors:  Kinnosuke Matsumoto; Takayuki Shiroyama; Tomoki Kuge; Kotaro Miyake; Yuji Yamamoto; Midori Yoneda; Makoto Yamamoto; Yujiro Naito; Yasuhiko Suga; Kiyoharu Fukushima; Shohei Koyama; Kota Iwahori; Haruhiko Hirata; Izumi Nagatomo; Yoshito Takeda; Atsushi Kumanogoh
Journal:  Transl Lung Cancer Res       Date:  2022-09

6.  Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis.

Authors:  E Suazo-Zepeda; M Bokern; P C Vinke; T J N Hiltermann; G H de Bock; G Sidorenkov
Journal:  Cancer Immunol Immunother       Date:  2021-06-30       Impact factor: 6.968

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.